- Home
- GIPR vs BIAF Comparison
GIPR vs BIAF Comparison
Compare GIPR & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GIPR | BIAF |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 6.8M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | GIPR | BIAF |
|---|---|---|
| Price | $0.65 | $1.23 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 744.9K | 74.4K |
| Earning Date | 11-17-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,953,920.00 | $6,776,739.00 |
| Revenue This Year | $1.12 | N/A |
| Revenue Next Year | $0.52 | $20.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.65 | $1.11 |
| 52 Week High | $2.06 | $46.53 |
Technical Indicators
Market Signals| Indicator | GIPR | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 33.97 | 36.15 |
| Support Level | $0.80 | $1.11 |
| Resistance Level | $0.77 | $1.37 |
| Average True Range (ATR) | 0.10 | 0.12 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 3.05 | 19.03 |
Price Performance
Historical ComparisonAbout GIPR Generation Income Properties Inc.
Generation Income Properties Inc is an internally managed real estate investment company focused on acquiring and managing income-producing retail, office and industrial properties net leased to high-quality tenants in markets throughout the United States. Its key source of revenue is the rental income. The company holds properties in Alabama, Arizona, Colorado, the District of Columbia, Florida, Illinois, North Carolina and Virginia.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.